2-bromo-1-(4-quinolinyl)ethanone hydrobromide | 36940-75-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2-bromo-1-(4-quinolinyl)ethanone hydrobromide
• 英文别名: 2-bromo-1-[4]quinolyl-ethanone; hydrobromide；2-Brom-1-[4]chinolyl-aethanon; Hydrobromid；2-Bromo-1-(4-quinolinyl)ethanone Hydrobromide；2-bromo-1-quinolin-4-ylethanone;hydrobromide
• CAS: 36940-75-7
• 化学式: BrH*C₁₁H₈BrNO
• 分子量: 331.007
• InChiKey: NULYQHPDNHSBLY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.39
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  30
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-bromo-1-(4-quinolinyl)ethanone hydrobromide 、 4-氯苯基硫脲 在 sodium carbonate 作用下， 以 乙醇 为溶剂， 以70%的产率得到N-(4-Chlorophenyl)-4-(quinolin-4-yl)-1,3-thiazol-2-amine
  参考文献：
  名称：

  新型 4-(6-取代喹啉-4-基)-N-芳基噻唑-2-胺衍生物作为潜在抗菌剂的合成和生物学评价

  摘要：

  4-（2-溴乙酰基）喹啉-1-鎓溴化物（4a-d）与取代的芳基硫脲（5a-g）的环缩聚反应得到4-（6-取代的喹啉-4-基）-N-芳基/吡啶基噻唑-2-胺（6a-ab）。评估了这些新合成的衍生物对大肠杆菌（NCIM 2574）、奇异变形杆菌（NCIM 2388）（革兰氏阴性菌株）、枯草芽孢杆菌（NCIM 2063）、白色葡萄球菌（NCIM 2178）（革兰氏阳性菌株）的体外抗菌活性) 和体外对黑曲霉的抗真菌活性(ATCC 504) 和白色念珠菌(NCIM 3100)。化合物6a、6b、6d、6f、6k和6l对S. albus显示出中等至良好的抗菌活性。10 种衍生物6c、6q、6r、6s、6t、6v、6w、6x、6y和6aa对A. niger显示出中等至良好的活性。N- [4-(Quinolin-4-yl)-1,3-thiazol-2-yl]pyridin-2-amine 对A. niger相对于标准药物鲁康唑。

  DOI：

  10.1002/jhet.4317
• 作为产物：
  描述：

  4-喹啉羰酰氯 在 氢溴酸 、 溴 、 溶剂黄146 、 三乙胺 作用下， 以 四氢呋喃 、 正己烷 、 二氯甲烷 为溶剂， 反应 21.0h， 生成 2-bromo-1-(4-quinolinyl)ethanone hydrobromide
  参考文献：
  名称：

  SAR studies of 4-pyridyl heterocyclic anilines that selectively induce autophagic cell death in von Hippel-Lindau-deficient renal cell carcinoma cells

  摘要：

  We recently identified a class of pyridyl aniline thiazoles (PAT) that displayed selective cytotoxicity for von Hippel-Lindau (VHL) deficient renal cell carcinoma (RCC) cells in vitro and in vivo. Structure-activity relationship (SAR) studies were used to develop a comparative molecular field analysis (CoMFA) model that related VHL-selective potency to the three-dimensional arrangement of chemical features of the chemotype. We now report the further molecular alignment-guided exploration of the chemotype to discover potent and selective PAT analogues. The contribution of the central thiazole ring was explored using a series of five-and six-membered ring heterocyclic replacements to vary the electronic and steric interactions in the central unit. We also explored a positive steric CoMFA contour adjacent to the pyridyl ring using Pd-catalysed cross-coupling Suzuki-Miyaura, Sonogashira and nucleophilic displacement reactions to prepare of a series of aryl-, alkynyl-, alkoxy- and alkylamino-substituted pyridines, respectively. In vitro potency and selectivity were determined using paired RCC cell lines: the VHL-null cell line RCC4 and the VHL-positive cell line RCC4-VHL. Active analogues selectively induced autophagy in RCC4 cells. We have used the new SAR data to further develop the CoMFA model, and compared this to a 2D-QSAR method. Our progress towards realising the therapeutic potential of this chemotype as a targeted cytotoxic therapy for the treatment of RCC by exploiting the absence of the VHL tumour suppressor gene is reported. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.04.042

文献信息

• [EN] HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT<br/>[FR] COMPOSÉS HÉTÉROARYLE, COMPOSITIONS ET PROCÉDÉS D'UTILISATION DANS LE TRAITEMENT DU CANCER
  申请人：UNIV LELAND STANFORD JUNIOR

  公开号：WO2009114552A1

  公开（公告）日：2009-09-17

  Provided herein are novel heteroaryl compounds, compositions comprising the compounds, and methods of treatment or prevention comprising administration of the compounds. The compounds are effective in the targeting of cells defective in the von Hippel-Lindau gene and in inducing autophagic cell death. The methods are directed to treating or preventing diseases such as cancer, and in particular cancers resulting from von Hippel-Lindau disease. The compounds of the invention may be administered in combination with another therapeutic agent.

  本文提供了新颖的杂环芳基化合物，包含这些化合物的组合物，以及包括给予这些化合物的治疗或预防方法。这些化合物在靶向冯·希普尔-林道（von Hippel-Lindau）基因缺陷细胞和诱导自噬性细胞死亡方面具有有效性。这些方法旨在治疗或预防癌症等疾病，特别是由冯·希普尔-林道疾病引起的癌症。本发明的化合物可以与另一种治疗剂联合给药。
• HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT
  申请人：Turcotte Sandra

  公开号：US20110105436A1

  公开（公告）日：2011-05-05

  Provided herein are novel heteroaryl compounds, compositions comprising the compounds, and methods of treatment or prevention comprising administration of the compounds. The compounds are effective in the targeting of cells defective in the von Hippel-Lindau gene and in inducing autophagic cell death. The methods are directed to treating or preventing diseases such as cancer, and in particular cancers resulting from von Hippel-Lindau disease. The compounds of the invention may be administered in combination with another therapeutic agent.

  本文提供了新型的杂环芳基化合物、包含这些化合物的组合物以及治疗或预防方法，包括给予这些化合物。这些化合物能够有效地针对von Hippel-Lindau基因缺陷的细胞，并诱导自噬性细胞死亡。这些方法旨在治疗或预防癌症等疾病，特别是由von Hippel-Lindau病引起的癌症。本发明的化合物可以与另一种治疗药物联合使用。
• SAR studies of 4-pyridyl heterocyclic anilines that selectively induce autophagic cell death in von Hippel-Lindau-deficient renal cell carcinoma cells
  作者：Muriel Bonnet、Jack U. Flanagan、Denise A. Chan、Edwin W. Lai、Phuong Nguyen、Amato J. Giaccia、Michael P. Hay

  DOI：10.1016/j.bmc.2011.04.042

  日期：2011.6

  We recently identified a class of pyridyl aniline thiazoles (PAT) that displayed selective cytotoxicity for von Hippel-Lindau (VHL) deficient renal cell carcinoma (RCC) cells in vitro and in vivo. Structure-activity relationship (SAR) studies were used to develop a comparative molecular field analysis (CoMFA) model that related VHL-selective potency to the three-dimensional arrangement of chemical features of the chemotype. We now report the further molecular alignment-guided exploration of the chemotype to discover potent and selective PAT analogues. The contribution of the central thiazole ring was explored using a series of five-and six-membered ring heterocyclic replacements to vary the electronic and steric interactions in the central unit. We also explored a positive steric CoMFA contour adjacent to the pyridyl ring using Pd-catalysed cross-coupling Suzuki-Miyaura, Sonogashira and nucleophilic displacement reactions to prepare of a series of aryl-, alkynyl-, alkoxy- and alkylamino-substituted pyridines, respectively. In vitro potency and selectivity were determined using paired RCC cell lines: the VHL-null cell line RCC4 and the VHL-positive cell line RCC4-VHL. Active analogues selectively induced autophagy in RCC4 cells. We have used the new SAR data to further develop the CoMFA model, and compared this to a 2D-QSAR method. Our progress towards realising the therapeutic potential of this chemotype as a targeted cytotoxic therapy for the treatment of RCC by exploiting the absence of the VHL tumour suppressor gene is reported. (C) 2011 Elsevier Ltd. All rights reserved.
• Synthesis and biological evaluation of novel 4‐(6‐substituted quinolin‐4‐yl)‐ <i>N</i> ‐aryl thiazol‐2‐amine derivatives as potential antimicrobial agents
  作者：Prashant Thakare、Abhijit Shinde、Sagar Dakhane、Abhijit Chavan、Vivek D. Bobade、Pravin C. Mhaske

  DOI：10.1002/jhet.4317

  日期：2021.9

  (5a–g) afforded 4-(6-substituted quinolin-4-yl)-N-aryl/pyridyl thiazol-2-amine (6a-ab). These newly synthesized derivatives were evaluated for in vitro antibacterial activity against Escherichia coli (NCIM 2574), Proteus mirabilis (NCIM 2388) (Gram-negative strains), Bacillus subtilis (NCIM 2063), Staphylococcus albus (NCIM 2178) (Gram-positive strains) and in vitro antifungal activity against Aspergillus

  4-（2-溴乙酰基）喹啉-1-鎓溴化物（4a-d）与取代的芳基硫脲（5a-g）的环缩聚反应得到4-（6-取代的喹啉-4-基）-N-芳基/吡啶基噻唑-2-胺（6a-ab）。评估了这些新合成的衍生物对大肠杆菌（NCIM 2574）、奇异变形杆菌（NCIM 2388）（革兰氏阴性菌株）、枯草芽孢杆菌（NCIM 2063）、白色葡萄球菌（NCIM 2178）（革兰氏阳性菌株）的体外抗菌活性) 和体外对黑曲霉的抗真菌活性(ATCC 504) 和白色念珠菌(NCIM 3100)。化合物6a、6b、6d、6f、6k和6l对S. albus显示出中等至良好的抗菌活性。10 种衍生物6c、6q、6r、6s、6t、6v、6w、6x、6y和6aa对A. niger显示出中等至良好的活性。N- [4-(Quinolin-4-yl)-1,3-thiazol-2-yl]pyridin-2-amine 对A. niger相对于标准药物鲁康唑。